Gent, Belgium: September 30, 2015 - Fujirebio Europe today announced the release of its new Lumipulse G Pepsinogen I and Pepsinogen II assays which will be immediately available for testing on its CLEIA-based LUMIPULSE G systems, the LUMIPULSE G600II and the LUMIPULSE G1200. Pepsinogen I levels and Pepsinogen I and II ratio are useful markers of chronic atrophic gastritis progression, which is strongly related with stomach cancer1. Patients with severe atrophic change typically have a higher frequency of cancer being found2,3.
“Pepsinogen I and II are important additional biomarkers in our rapidly expanding Lumipulse G tumor marker panel.” said Christiaan De Wilde, CEO at Fujirebio Europe. “Our company has already been known as the gold standard in oncology IVD testing for many years and the new Pepsinogen markers confirm our firm intention to extend this worldwide leadership to routine testing solutions through our LUMIPULSE G systems.”
Please contact your local sales representative for the availability of these products in your country. These products are not available in the US and in Canada.
Fujirebio is a leading international healthcare company with a strong focus on high quality in vitro diagnostics (IVD) testing solutions. Founded more than 60 years ago in Japan, the company is today recognized as the world-wide market leader in oncology for both routine and novel markers and has a strong reputation in Japan in infectious disease testing in hospitals, clinical labs and blood banks. Over the last 20 years Fujirebio has been committed to bringing solid and successful automated immunoassay testing solutions and state of the art chemiluminescent assay products to the market. Under the name Innogenetics (now Fujirebio Europe) the company has also been pioneering the field of molecular diagnostics and multiparameter testing. The company is today one of the world leaders in strip-based diagnostics solutions.
The product lines range from specialized manual testing to fully automated routine testing and they cover disease fields such as infectious, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone.
Fujirebio is a subsidiary of Japan-based Miraca Holdings (listed in the Tokyo Stock Exchange - MRCHF) and counts more than 1.100 employees working in Asia, Europe and America, including subsidiaries. For more information about Fujirebio please visit www.fujirebio.com/english or www.fujirebio-europe.com.
Sanloff IP, et al. Relationships among serum pepsinogen I, serum pepsinogen II and gastric mucosal histology. Gastroenterology, 83: 204-209, 1982.
Miki K. Gastric Cancer Screening Using Serum Tests (Stomach Dry Dock) – Study of the Systems of the First Screening for Cancer-susceptible Subjects by Serum Pepsinogen Levels and the Secondary Close-examination by Every-Other-Year Panendoscopy. Nippon Shokaki shudankenshin gakkaishi, 84: 141-144, 1989.
Nishizawa M. An outlook of gastric mass screening (1st report). Nippon Shokaki shudankenshin gakkaishi, 84: 141-144, 1989.